# DBV Technologies S.A. (DBVT)

> Source: Nexqual · https://nexqual.com/DBVT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, DBV Technologies S.A. (DBVT), nexqual.com/DBVT" · informational, not investment advice.

**Price:** USD 9.11 (+2.71% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 8.87 · day 8.85–9.21 · 52w 8.85–26.19 · market cap $573M · NCM

## Key facts
- Analysts: Buy (mean 2.14 on a 1–5 scale) (7 analysts), mean target USD 38.69 (range 5.71–54.5).
- Total return with dividends: 1Y -46.4% vs S&P 500 +18.1%; 5Y -14.1% vs S&P 500 +85.1%.
- Next earnings: 2026-10-28, EPS estimate USD -0.15, revenue estimate $582K.

## Analysts
Consensus Buy (mean 2.14 on a 1–5 scale), 7 analysts; mean target USD 38.69 (low 5.71, high 54.5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-30 | Citizens | Target raised | Market Outperform | $47 → $55 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -46.4% | -14.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -46.5% | -3.0% |
| Volatility (annualized) | 68.6% | 121.5% |
| Max drawdown | -63.9% (Jan 2026→Oct 2026) | -95.8% (Oct 2021→Nov 2024) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/DBVT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt